|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00150332 |
|
Date of registration:
|
06/09/2005 |
|
Primary sponsor: |
|
|
Public title:
|
Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan
|
|
Scientific title:
|
Linezolid (PNU-10766/PNU10766SS) in the Treatment of MRSA Infections in Patients Whose Conventional Therapy Has Failed, or Who Are Intolerant to Conventional Therapy; an Open-label, Multi-center Trial |
|
Date of first enrolment:
|
January 2003 |
|
Target sample size:
|
24 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00150332 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
Japan
| | | | | | | |
|
Contacts
|
|
Name:
|
Pfizer CT.gov Call Center |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Pfizer |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- infection due to methicillin-resistant Staphylococcus aureus
Exclusion Criteria:
- hypersensitivity to linezolid
Age minimum:
16 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Infections, Nosocomial
|
|
Intervention(s)
|
|
Drug: linezolid
|
|
Primary Outcome(s)
|
|
Resolution of infection at the time of completion of therapy
|
|
Secondary Outcome(s)
|
|
Adverse events
|
|
Secondary ID(s)
|
|
A5951054
|
|
M12600067
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|